STAT

Sequencing patients’ genomes might not break the health care bank, study finds

The first rigorous study of its kind finds that sequencing people’s genomes might not lead to extensive and expensive follow-up screening and care.

The first rigorous study of its kind finds that sequencing people’s genomes might not lead to extensive and expensive follow-up care, researchers reported on Thursday.

“That’s been the critical question that has the field [of medical genetics] very concerned: Will whole-genome sequencing drive up downstream costs?” said Kurt Christensen of Brigham and Women’s Hospital in Boston, lead author of the study in Genetics in Medicine.

To find out, he and his colleagues recruited 100 healthy adults and 100 patients with cardiomyopathy, assigning roughly half of each

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related